Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Recent Pat Biotechnol. 2021 Oct 4;15(2):112-136. doi: 10.2174/1872208315666210419103742.
Viral respiratory infections could result in perturbation of the gut microbiota due to a probable cross-talk between lungs and gut microbiota. This can affect pulmonary health and the gastrointestinal system.
This review aimed to discuss the impact of probiotics/prebiotics and supplements on the prevention and treatment of respiratory infections, especially emerging pathogens.
The data were searched in PubMed, Scopus, Google Scholar, Google Patents, and The Lens-Patent using keywords of probiotics and viral respiratory infections in the title, abstract, and keywords.
Probiotics consumption could decrease the susceptibility to viral respiratory infections, such as COVID-19 and simultaneously enhance vaccine efficiency in infectious disease prevention through the immune system enhancement. Probiotics improve the gut microbiota and the immune system via regulating the innate system response and production of anti-inflammatory cytokines. Moreover, treatment with probiotics contributes to intestinal homeostasis restitution under antibiotic pressure and decreasing the risk of secondary infections due to viral respiratory infections. Probiotics present varied performances in different conditions; thus, promoting their efficacy through combining with supplements (prebiotics, postbiotics, nutraceuticals, berberine, curcumin, lactoferrin, minerals, and vitamins) is important. Several supplements reported to enhance the probiotics' efficacy and their mechanisms as well as probiotics- related patents are summarized in this review. Using nanotechnology and microencapsulation techniques can also improve probiotics' efficiency.
Given the global challenge of COVID-19, probiotic/prebiotic and following nutritional guidelines should be regarded seriously. Additionally, their role as an adjuvant in vaccination for immune response augmentation needs attention.
病毒呼吸道感染可能会由于肺部和肠道微生物群之间的可能交叉对话而导致肠道微生物群失调。这会影响肺部健康和胃肠道系统。
本综述旨在讨论益生菌/益生元和补充剂对预防和治疗呼吸道感染,特别是新兴病原体的影响。
使用益生菌和病毒性呼吸道感染在标题、摘要和关键词中的关键词,在 PubMed、Scopus、Google Scholar、Google Patents 和 Lens-Patent 中搜索数据。
益生菌的摄入可以降低对病毒性呼吸道感染的易感性,例如 COVID-19,并通过增强免疫系统同时提高传染病预防疫苗的效率。益生菌通过调节先天系统反应和产生抗炎细胞因子来改善肠道微生物群和免疫系统。此外,益生菌治疗有助于在抗生素压力下恢复肠道内稳态,并降低因病毒性呼吸道感染引起的二次感染风险。益生菌在不同条件下表现出不同的性能;因此,通过与补充剂(益生元、后生元、营养保健品、黄连素、姜黄素、乳铁蛋白、矿物质和维生素)结合来促进其功效很重要。本文总结了几种被报道能增强益生菌功效及其机制的补充剂,以及与益生菌相关的专利。使用纳米技术和微胶囊技术也可以提高益生菌的效率。
鉴于 COVID-19 的全球挑战,益生菌/益生元和后续营养指南应得到认真对待。此外,还需要关注它们作为免疫反应增强疫苗辅助剂的作用。